Alliance for the Prudent Use of Antibiotics
The mission of the Alliance for the Prudent Use of Antibiotics (APUA) is to strengthen global defenses against infectious disease by ensuring access to effective treatment and promoting appropriate antibiotic use to contain drug resistance. With a network of affiliated chapters in 19 countries, APUA stands as the world’s leading organization conducting research and education on antimicrobial treatment and resistance at the grassroots and global levels.
Alliance for the Prudent Use of Antibiotics (APUA)
Now under the auspices of the
International Society of Antimicrobial Chemotherapy (ISAC)
Stuart’s retirement was an opportunity for the APUA Board to review its leadership and governance and it took the opportunity to seek a partner organisation with which to synergise. This led to the merger of APUA with the International Society of Antimicrobial Chemotherapy (ISAC), effective from February 2019. ISAC was founded as a charity in 1961 and, in response to the dynamic nature of the subject matter, has focused most recently on antimicrobial stewardship and antimicrobial resistance.
The boards of the ISAC Antimicrobial Stewardship Working Group and APUA have merged to form the following new APUA Board:
The continuing mission of APUA is to maximise the effectiveness of antimicrobial treatment by promoting appropriate antimicrobial use and containing drug resistance.
APUA and ISAC will retain their own identities.
The launch of APUA under the auspices of ISAC will be kick started with a joint newsletter and reception during ECCMID in Amsterdam in April and the announcement of a new plan of work for APUA.
For more information on ISAC, visit ischemo.org.
Please contact email@example.com for further information.
APUA President Stuart B. Levy announces retirement from Tufts
APUA signs onto REVAMP Act of 2018
Gordon William Grundy, MD (1944-2018)
New U.S. bill introduced to increase oversight of antibiotic use in animals
Canada urges action, federal leadership, for AMR problem
Tripartite memorandum steps up ‘One Health’ agenda
New guidance released for building health worker knowledge and hospital
EU coalition (EU-JAMRA) seeks national action plans for member states
New guidelines issued for C. difficilemanagement
FDA to implement five-year blueprint for antimicrobial stewardship in farm animals
Innovet-AMR: a new partnership seeks alternatives in livestock, aquaculture
Ghana launches antimicrobial resistance policy
Novartis abandons antimicrobial development
Moving beyond antibiotics: the prospects for bacteriophage therapy
Roundworms help identify antibacterial properties of retinoids
Teixobactin development takes ‘quantum leap’
Synthetic polymers as antibiotics
Soil-dwelling nematodes yield novel antimicrobial
Turning MRSA on itself
Using computer algorithms to develop antibiotics
Antibiotic supply chain “fragile” – deepens resistance crisis
Lord O’Neill castigates pharma industry and European farmers for inaction
Repeated low-level antibiotic exposure yields high level resistance
More challenging superbugs on the horizon: pan-resistant infections on the rise
Salmonella typhi approaching pan-resistance
Triple threat posed by Klebsiella
First “super gonorrhea” appears in England
Plasmid transfer found among unrelated hospital bacteria
CPE control — a losing battle?
Mechanics of gene transfer visualized for the first time
Drug users more susceptible to MRSA infection
Microplastics promote gene transfer in aquatic environments
Triclosan exposure yields antibiotic-resistant mutants
Publications of Interest
APUA WELCOMES NEW BOARD MEMBERS
APUA is proud to announce the addition of five new members to our Board of Directors:
Robert Gaynes, MD, Professor - Department of Medicine - Emory School of Medicine
Shahin Gharakhanian, MD - Cambridge Innovation Center
Cristina Larkin, Chief Commercial Officer - Spero Therapeutics
Margaret Riley, PhD, Professor - Department of Biology - University of Massachusetts, Amherst
David White, PhD, Associate Dean of Research - University of Tennessee School of Agriculture
You can view the complete list of APUA Board members
APUA extends its deepest thanks to Dennis Signorovitch as he completes 10 years of outstanding service as a member of APUA's Board of Directors. His leadership, advice and enthusiasm have aided the organization immeasurably in forwarding its mission and we wish him well in all his future endeavors. Thank you, Dennis!
"Antibiotics are uniquely societal drugs because individual use affects others in the community and environment. Better stewardship, incentives, and establishment of a special regulatory category will improve how they are used, marketed, and developed through incentives to industry."
Stuart B. Levy, M.D.
President of APUA, professor at Tufts University School of Medicine
From the IOM 25th Anniversary Symposium (1996) and The Antibiotic Paradox (2002)
In case you missed it, our latest webinar
is now available for streaming